TransCode Therapeutics
RNAZ
Market cap $5.82M

0.3370 USD

-0.0027

0.79%

Updated Nov 18, 1:24 PM EST

1 day

-0.79%

5 days

-13.59%

1 month

-45.03%

3 months

24.86%

6 months

-71.68%

Year to date

-94.78%

1 year

-96.32%

5 years

-99.99%

10 years

-99.99%

About: TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Employees: 10

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,704 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

2.23% less ownership

Funds ownership: 4.11% [Q2] → 1.88% (-2.23%) [Q3]

32% less capital invested

Capital invested by funds: $273K [Q2] → $186K (-$87.3K) [Q3]

40% less funds holding

Funds holding: 15 [Q2] → 9 (-6) [Q3]

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

790%

upside

Avg. target

$3

790%

upside

High target

$3

790%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Emily Bodnar 25% 1-year accuracy 34 / 136 met price target	790%upside $3	Buy Reiterated	15 Nov 2024
HC Wainwright & Co. Emily Bodnar 25% 1-year accuracy 34 / 136 met price target	790%upside $3	Buy Reiterated	24 Oct 2024
HC Wainwright & Co. Emily Bodnar 25% 1-year accuracy 34 / 136 met price target	790%upside $3	Buy Reiterated	6 Sept 2024

See Analyst Rankings

Financial journalist opinion

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode's request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D).

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleotide conjugated to TransCode's proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers Phase 1 clinical trial follows evidence of delivery and pharmacodynamic activity in prior first-in-human Phase 0 clinical trial with radiolabeled TTX-MC138 BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced dosing of the first two patients in its Phase 1 clinical trial with its lead candidate, TTX-MC138.

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate.

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?

TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Tuesday after the biopharmaceutical company announced the pricing for a public offering of its shares. TransCode Therapeutics is selling 10 million shares of its common stock for 30 cents each.

Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Company has regained compliance with all applicable Nasdaq listing standards. As a result, the Company's stock will remain listed and traded on the Nasdaq Stock Market.

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity. New results from the patient dosed in this trial indicate that a microdose of radiolabeled TTX-MC138 resulted in significant inhibition of the drug candidate's molecular target, miRNA-10b, in the patient's blood.

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?

TransCode Therapeutics (NASDAQ: RNAZ ) stock is sliding lower on Monday following its announcement of an upcoming annual shareholder meeting. TransCode Therapeutics has informed investors in RNAZ stock that the company will hold its annual shareholder meeting on June 13, 2024 at 9:30 a.m Eastern Time.

Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?

See News Rankings

Charts implemented using Lightweight Charts™